Evidence map›Paper›PMID 27148571›Full record

ArticleCold Spring Harbor molecular case studies2015

Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma.

Sarah Tannenbaum-Dvir, Julia L Glade Bender, Alanna J Church, Katherine A Janeway, Marian H Harris, Mahesh M Mansukhani, Peter L Nagy, Stuart J Andrews, Vundavalli V Murty, Angela Kadenhe-Chiweshe and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Case report:Frontiers in oncology · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. What's new in fibroblastic tumors?Virchows Archiv : an international journal of pathology · 2020
    Review
  16. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2019
    Review
  17. Detection ofCancer research · 2019
    Review
  18. Review
  19. Refractory and metastatic infantile fibrosarcoma harboringCold Spring Harbor molecular case studies · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sarah Tannenbaum-DvirColumbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA;
Julia L Glade BenderColumbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA;
Alanna J ChurchHarvard Medical School, Department of Pathology, Boston, Massachusetts 02115, USA;
Katherine A JanewayHarvard Medical School, Department of Pediatric Oncology/Hematology, Boston, Massachusetts 02115, USA;
Marian H HarrisHarvard Medical School, Department of Pathology, Boston, Massachusetts 02115, USA;
Mahesh M MansukhaniColumbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA;
Peter L NagyColumbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA;
Stuart J AndrewsColumbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA;
Vundavalli V MurtyColumbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA;
Angela Kadenhe-ChiwesheColumbia University Medical Center, Department of Surgery, New York, New York 10032, USA;
Eileen P ConnollyColumbia University Medical Center, Department of Radiation Oncology, New York, New York 10032, USA.
Andrew L KungColumbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA;
Filemon S Dela CruzColumbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA;

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the clinical course of a recurrent case of congenital fibrosarcoma diagnosed in a 9-mo-old boy with a history of hemimelia. Following complete surgical resection of the primary tumor, the patient subsequently presented with bulky bilateral pulmonary metastases 6 mo following surgery. Molecular characterization of the tumor revealed the absence of the prototypical ETV6-NTRK3 translocation. However, tumor characterization incorporating cytogenetic, array comparative genomic hybridization, and RNA sequencing analyses, revealed a somatic t(2;15)(2p21;15q25) translocation resulting in the novel fusion of EML4 with NTRK3. Cloning and expression of EML4-NTRK3 in murine fibroblast NIH 3T3 cells revealed a potent tumorigenic phenotype as assessed in vitro and in vivo. These results demonstrate that multiple fusion partners targeting NTRK3 can contribute to the development of congenital fibrosarcoma.

Indexed as

abnormality of the musculature of the limbscongenital fibrosarcoma

Identifiers

PMID27148571
PMCPMC4850889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.